ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
The three-month period ending December 31, 2025, preliminary net product revenue of approximately $38.3 million, surpassing net product revenue of $31.8 million in the prior quarter, a 20% quarter over quarter increase and a 431% increase over the three-month period ended December 31, 2024 ANKTIVA Unit Growth: 750% unit sales volume growth in 2025 compared to 2024 Approval Updates: The Saudi FDA (SFDA) granted approval of ANKTIVA ® in combination with immune checkpoint inhibitors for adults with metastatic non-small cell lung cancer (NSCLC) who have failed standard therapies — marking the Company's first global approval for this indication and the first approval of ANKTIVA for subcutaneous administration The SFDA also approved ANKTIVA ® in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), adding to existing approvals in the U.S. and U.K., and conditional approval in the European Union Enrollment in the on
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% [Yahoo! Finance]Yahoo! Finance
- ImmunityBio: Why I Am Upgrading To A Buy For 2026 [Seeking Alpha]Seeking Alpha
- ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-yearBusiness Wire
- Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ [Yahoo! Finance]Yahoo! Finance
- Update: ImmunityBio Gets Approval From Saudi FDA For Non-Muscle Invasive Bladder Cancer Treatment; Shares Rise [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/15/26 - Form 8-K
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- IBRX's page on the SEC website